Pfizer, BMS Aim To Block Generic In Blood Thinner IP Fight

Law360, London (May 12, 2021, 12:18 PM BST) -- Pfizer and a subsidiary of Bristol Myers Squibb have hit back at an attempt by Teva to invalidate patents for development of a blockbuster blood thinner, saying the generic drugmaker's planned thrombosis treatment infringes its patents.

Bristol-Myers Squibb Holdings Ireland Unlimited Co. and Pfizer Inc. pushed back in an amended High Court defense and counterclaim against the lawsuit brought by Teva Pharmaceuticals, which asserts that none of the elements stated within the patents create a new, patentable invention.

And the companies say in the April 30 filing, which recently became public, that unless Teva is restrained by the High Court it will...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!